Ketamine Cystitis and Sexual Dysfunction in Women: A 2011 Case-Control Study

Introduction

In a significant study published in BJU International on December 16, 2011, Jang et al. examined the relationship between ketamine cystitis (KC) and sexual dysfunction in women. This research offers valuable insights into the broader impact of chronic ketamine use on female patients’ quality of life, emphasizing the importance of multidisciplinary care.

Key Points

  1. Study Design
    • This case-control study involved women diagnosed with ketamine cystitis compared to a control group without urinary symptoms.
    • Standardized surveys assessed sexual function, focusing on dimensions like desire, arousal, pain, and satisfaction.
  2. Results
    • Women with ketamine cystitis reported significantly higher rates of sexual dysfunction.
    • Key findings included:
      • Increased pain during intercourse (dyspareunia).
      • Decreased sexual desire and overall satisfaction.
    • The study suggests that bladder pain and associated symptoms may contribute to psychological and physiological barriers to sexual health.
  3. Clinical Implications
    • Ketamine cystitis extends beyond urological symptoms, necessitating a holistic approach to patient care.
    • Providers should consider routine sexual health assessments in women with KC to address potential concerns early.
  4. Broader Impact
    • As ketamine use continues to grow in medical and recreational contexts, awareness of its long-term effects is crucial for prevention and intervention.

The VitalPoint For Providers

This study underscores the need for healthcare professionals to adopt an integrative approach when treating women with ketamine cystitis. Regularly screening for sexual dysfunction and offering interdisciplinary support—combining urology, gynecology, and mental health services—can significantly improve patient outcomes.

Relevance to Providers: This research provides actionable data to help clinicians identify and address an often-overlooked aspect of care for women with ketamine-related bladder dysfunction.

Further Reading:

Ketamine Provider Research
VitalPoint Technologies, Inc.

Disclaimer

None of the statements in this announcement or via any web sites linked herein have been evaluated by the FDA. Furthermore, none of the statements in this announcement or any web sites linked herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.

Scroll to Top